20/20 Biolabs, Inc. · NASDAQ:AIDX
20/20 Biolabs — Investor Presentation (August 2026)
17 slides from 20/20 Biolabs's investor presentation, Aug 5, 2026
Slide 1: Investor Webinar August 5, 2026
NASDAQ: AIDX Investor Webinar August 5, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information c
Slide 3: Today's Presentation
Today's Presentation • Overview of AIDX (5-minutes; for 1st time attendees) • Updates & Progress since July Webinar (25 minutes) o Commercial Progress & New Customers (David Lees) o Giant Pharmacy Pilot of Longevity Test o East Asia Trip (Jonathan Cohen) • Q&A (10-15 minutes)
Slide 4: Congress Creates a Pathway for Medicare Reimbursement for Multi-Cancer Tests by 2028
Congress Creates a Pathway for Medicare Reimbursement for Multi- Cancer Tests by 2028 • Establishes the first statutory pathway for Medicare coverage of MCED blood tests • CMS authority to reimburse MCEDs beginning in 2028 • Applies to FDA-approved MCED tests deemed clinically appropriate by CMS • I
Slide 5: Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri
Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri • Primary endpoint missed — no drop in combined Stage III/IV cancers overall • Stage I–II diagnoses rose just 16% when added to standard screening — unlikely to translate into a meaningful mortality benefit • ctDNA mis
Slide 6: OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet
OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet Biomarker Panel: 12 Markers Cancer protein tumor markers (PTMs) • AFP — liver, testicular, ovarian • CEA — lung, pancreatic, GI • CA 19-9 — pancreatic, liver, GI • CA 125 — ovarian, lung • CYFRA 21-1 — lung, head/ne
Slide 7: OneTest Advantages Over ctDNA — Our "Straight A's"
OneTest Advantages Over ctDNA — Our "Straight A's" • Accuracy for Earlier Stage Cancers • Affordability • Acceleration over Time • Aggregates Data from Multiple Sources • Access at Home & Workplaces • AI Compatible for Consumers & Clinicians
Slide 8: At Home Capillary Collection Now Makes Quarterly Testing Practical & Velocity Algorithms Impactful
8 At Home Capillary Collection Now Makes Quarterly Testing Practical & Velocity Algorithms Impactful
Slide 9: M&A Strategy
9 Expect to "bolt-on" or acquire other companies that are vertically or horizontally integrated with 20/20 (e.g., suppliers, distributors, or related products) M&A Strategy Desired Attributes for Acquired Companies • Health & wellness customer base overlaps with those of 20/20 - Early Cancer Detecti
Slide 10: How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth
10 How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth 4 4 2 39 99 266 0 50 100 150 200 250 300 2012 2013 2014 2015 2016 2017 Annual Revenue ($M) ← Medicare Coverage October 2014 FDA Approval Aug 11, 2014 — First stool DNA test approved Medicare NCD Issued Oct 9, 2014 — Coverag
Slide 11: Revenue Projections & Royalty Pool Sharing Following Medicare Reimbursement
Revenue Projections & Royalty Pool Sharing Following Medicare Reimbursement Based on 20% Premium over Exact Sciences (Cologuard) Five percent royalty pool on revenues over first 5 years ~ $100 million Royalty pool to be shared with "data investors" on a pro-rata basis Revenue projections (in $millio
Slide 12: Q2 2026 Sales Update
Q2 2026 Sales Update • Q2 2026 produced our best quarterly cancer testing revenue to date, based on preliminary, unaudited results. • We believe both Q3 and Q4 2026 will show strong year- over-year revenue growth. o Preliminary results may change pending our quarterly close; final results will be re
Slide 13: Q2 2026 Sales Update: Major Wins
Q2 2026 Sales Update Major Wins • 29 Orders from New Accounts o Including Occupational and Preventive Health Companies, Fire Departments, and Primary Care Physicians • Maryland Firefighter Cancer Screening Program o 18 Fire Departments o 1,400+ participants • Selected for Vermont Firefighter Cancer
Slide 14: New Customers
New Customers • Momentum with new customers continues into Q3 • Highlights o Strong growth with new customers in the Fire Department, Occupational Health, Military service, and Physician Practice Markets o TF – 7294 Foundation Executed purchase agreement expanding access to OneTest for Cancer to the
Slide 15: New Pilot with Giant Food — OneTest for Longevity
New Pilot with Giant Food — OneTest for Longevity • Pilot term: 3-month pilot expected to begin in August 2026 • Product: OneTest for Longevity, measuring inflammatory and cardiometabolic biomarkers, run at our CAP-accredited, high-complexity CLIA lab in Gaithersburg, MD. • Two channels at participa
Slide 16: CEO's Two-Week East Asia Trip
CEO's Two-Week East Asia Trip • CEO Jonathan Cohen recently completed a two-week trip across East Asia (Taipei, Tokyo, Seoul). • Anticipated results from the trip include: o Commercial expansion in the region o Acquisition of real-world data for use with U.S. regulators and payors o Merger and acqui
Slide 17: Key Takeaway
Key Takeaway: AIDX has the upside potential of a biopharmaceutical company (in Phase II clinical trials) with the downside protection of an early revenue stage Dx or medtech company Jonathan Cohen CEO 240-453-6343 Investors@2020Biolabs.com NASDAQ: AIDX 2020biolabs.com